Anti-angiogenic Therapy for Lung Cancer: Focus on Bioassay Development in a Quest for Anti-VEGF Drugs

Authored by: Urvashi Bhati , Colin J. Barrow , Jagat R. Kanwar , Arnab Kapat , Venkata Ramana , Rupinder K. Kanwar

Handbook of Lung Targeted Drug Delivery Systems

Print publication date:  October  2021
Online publication date:  October  2021

Print ISBN: 9780367490676
eBook ISBN: 9781003046547
Adobe ISBN:


 Download Chapter



The ongoing discovery of novel molecules involved in signaling pathways leading to cancer development has no doubt led to the rapid expansion of targeted-agents development in oncology. Owing to the quality-of-life issues and high mortality rates associated with lung cancer, it has been realized that to have better survival outcomes for patients, there is a marked need for additional targeted therapeutic options than the standard chemo and immunotherapeutics. Angiogenesis is one such fundamental process being constantly targeted to develop new therapeutic molecular agents. Vascular endothelial growth factor (VEGF) is the key angiogenic factor and anti-VEGF/VEGFR2 drugs have now emerged as the leading category of anti-cancer drugs. Here the therapeutic agent functions by blocking the ligand, VEGF or its receptor, VEGFR2, and as a result angiogenesis of tumor cells is arrested which eventually halts their proliferation and survival. Further, the recent preclinical evidence demonstrates the potential of anti-angiogenic therapy to target immunosuppression in the tumor microenvironment and trigger an “angio-immunogenic switch” back toward an immunosupportive environment

Search for more...
Back to top

Use of cookies on this website

We are using cookies to provide statistics that help us give you the best experience of our site. You can find out more in our Privacy Policy. By continuing to use the site you are agreeing to our use of cookies.